Mr. Feng Zhou has been our CEO and director since July 4, 2017. He was the CEO of Taizhou Suxuantang, our VIE Entity from May 2017 to February, 2018. From January 2015 to May 2017, he was the vice manager of Taizhou Suxuantang. As vice manager of Taizhou Suxuantang, he was responsible for procurement and formulating a cost effective strategy for purchasing goods and services.  Mr. Zhou graduated from Logistical Engineering University of PLA and majored in Business Administration. We believe that Mr. Zhou should serve as a member of our board of directors due to the perspective and experience he brings as our founder, Chairman, and CEO, and as our largest and controlling stockholder.

Dr. Jingzhen Deng has been our CSO since June 2013, our COO since March 2017 and CEO of Taizhou Suxuantang since February, 2018. He has been the vice president of Taizhou Suxuantang in June 2013 and rebuilt its R&D team. Dr. Deng has 16 years of experience at a university (University of Virginia as a postdoctoral scientist) and various pharmaceutical companies (Pinnacle Pharmaceuticals, Inc. and Drumetix Laboratories, as directors of R&D) specializing in natural products and new drug discovery in the USA, and more than 14 years at a Traditional Chinese Medicine (“TCM”) related university (China Pharmaceutical University), institute (Jiangxi Institute of TCM), and pharmaceutical company (RCT Pharmaceuticals, Inc. as CEO in Shanghai) in China. He established the general R&D strategy of using modern technology to revolutionize TCMP production, and continue developing newly advanced and non-decocting TCMP/TCM products capable of meeting the highest quality standard at the company. Dr. Deng received his Bachelor of Science from Jiangxi University of Traditional Chinese Medicine in 1982, Master and Doctoral degrees from China Pharmaceutical University in 1989 and 1992, respectively.

Mr. Yao Shi has been our CFO of China SXT pharmaceuticals, Inc. since March, 2017. Mr. Shi is well suited for this position with more than 20 years of experience in auditing and accounting. From July 2006 to March 2017, Mr. Shi was CFO and Chief Manager of Guotaijiahe Insurance Co. Ltd. From November 1996 to June 2009, Mr. Shi was the CFO of Amway China North China Branch. Mr. Shi holds a MBA from Victoria University and a Bachelor degree from Changchun University of Science and Technology. 

Mr. Jun Zheng will be appointed as our executive director of China SXT Pharmaceuticals, Inc. upon closing of the Nasdaq IPO. Mr. Zheng was a sales area manager at Jiangxi Bo Shi Da Pharmaceutical Co., Ltd. from 1999 to 2004, and a department manager & a deputy general manager at Taizhou Jiutian Pharmaceutical Co., Ltd. from the 2005 to 2012. Mr. Zheng served as a general manager at Taizhou Renji Chinese Traditional Medicine Pieces Co., Ltd. from 2013 to 2015 and a general manager at Jiangsu Health Pharmaceutical Investment Management Co., Ltd. from 2016 to 2017. Currently, Mr. Zheng is a vice president at Jiangsu Suxuantang Pharmaceutical Co. Ltd.Mr. Zhengreceived his Bachelor degree from Jiangnan University (Wuxi Light Industry University) in 1999.

Dr. Junsong Li will be appointed as our independent director of China SXT Pharmaceuticals, Inc.  upon closing of the Nasdaq IPO. Dr. Li has over 20 year-experience in the TCM industry. He has served as the researcher of Nanjing TCM University since 2009. From 1986 to 2003, Dr. Li worked as an associate professor of Nanjing TCM Hospital. Dr. Li graduated from Nanjing TCM University with a Bachelor of Arts in TCM in 1986 and a Master’s Degree in TCM in 2002. He obtained his PhD from Shanghai TCM University in 2006. We believe Dr. Li is well-qualified to serve as a member of the board because of her extensive prior work experience and educational background in the TCM field. 

Dr. Tulin Lu will be appointed as our independent director of China SXT Pharmaceuticals, Inc.  upon closing of the Nasdaq IPO. Currently, Dr. Lu is a Professor at Nanjing University of TCM. As a veteran in the TCM academia, Dr. Lu has also served as the Chief Director at the co-laboratory of TCM Processing of Ministry of Education of the P. R. China since 2012, the Deputy Director of the standard laboratory of TCM pieces at the State Administration of TCM of the P. R. China since 2008, the Deputy Director at Jiangsu Provincial Key Laboratory of the Processing of TCM since 2007, the Deputy Director of the department of Processing preparation of TCM at Nanjing University of TCM since 2016, and the Executive Deputy Director of TCM Pieces Quality Assurance Specialized Committee of China since 2014. Dr. Lu received his Ph. D, Master of Science, and Bachelor of Science degrees from Nanjing University of TCM in 1989, 1999, and 2003, respectively. 

Mr. Wenwei Fan will be appointed as our independent director of China SXT Pharmaceuticals, Inc. upon closing of the Nasdaq IPO. Mr. Fan currently is a Partner of a Chinese Certified Public Accountant firm, Beijing Huashen Accounting Firm, where he is in charge of supervising international auditing, including auditing financial statements for Chinese subsidiaries of several multinational companies. He started his career with ShiyongZhonghe Accounting firm, which was acquired by PricewaterHouseCoppers in 2000. Mr. Fan is a Certified Public Accountant and Certified Tax Agent in China. He graduated from Jingsu University of Finance and Economics in 1992 with a bachelor’s degree.

Address:No.178 North Taidong Road, Taizhou, Jiangsu, 225300, P. R. China Contact Number:+86-523-86299087 E-mail:[email protected]
Copyright (C) 2017 China SXT Pharmaceuticals, Inc 蘇ICP備14058902號-2 【Disclaimer】